DOI QR코드

DOI QR Code

Antiviral Activity of Fritillaria thunbergii Extract against Human Influenza Virus H1N1 (PR8) In Vitro, In Ovo and In Vivo

  • Kim, Minjee (Department of Biomedical Science and Engineering, Konkuk University) ;
  • Nguyen, Dinh-Van (Department of Biomedical Science and Engineering, Konkuk University) ;
  • Heo, Yoonki (Department of Biomedical Science and Engineering, Konkuk University) ;
  • Park, Ki Hoon (Department of Biomedical Science and Engineering, Konkuk University) ;
  • Paik, Hyun-Dong (Department of Food Science and Biotechnology of Animal Resources, Konkuk University) ;
  • Kim, Young Bong (Department of Biomedical Science and Engineering, Konkuk University)
  • Received : 2019.08.02
  • Accepted : 2019.11.14
  • Published : 2020.02.28

Abstract

Influenza viruses cause respiratory diseases in humans and animals with high morbidity and mortality rates. Conventional anti-influenza drugs are reported to exert side effects and newly emerging viral strains tend to develop resistance to these commonly used agents. Fritillaria thunbergii (FT) is traditionally used as an expectorant for controlling airway inflammatory disorders. Here, we evaluated the therapeutic effects of FT extracts against influenza virus type A (H1N1) infection in vitro, in ovo, and in vivo. In the post-treatment assay, FT extracts showed high CC50 (7,500 ㎍/ml), indicating low toxicity, and exerted moderate antiviral effects compared to oseltamivir (SI 50.6 vs. 222) in vitro. Antiviral activity tests in ovo revealed strong inhibitory effects of both FT extract and oseltamivir against H1N1 replication in embryonated eggs. Notably, at a treatment concentration of 150 mg/kg, only half the group administered oseltamivir survived whereas the FT group showed 100% survival, clearly demonstrating the low toxicity of FT extracts. Consistent with these findings, FT-administered mice showed a higher survival rate with lower body weight reduction relative to the oseltamivir group upon treatment 24 h after viral infection. Our collective results suggest that FT extracts exert antiviral effects against influenza H1N1 virus without inducing toxicity in vitro, in ovo or in vivo, thereby supporting the potential utility of FT extract as a novel candidate therapeutic drug or supplement against influenza.

Keywords

References

  1. Moscona A. 2005. Neuraminidase inhibitors for influenza. N. England J. Med. 353: 1363-1373. https://doi.org/10.1056/NEJMra050740
  2. Liu M, Zhao X, Hua S, Du X, Peng Y, Li X, et al. 2015. Antigenic patterns and evolution of the human influenza A (H1N1) virus. Sci. Rep. 5: 14171. https://doi.org/10.1038/srep14171
  3. Rewar S, Mirdha D, Rewar P. 2015. Treatment and prevention of pandemic H1N1 Influenza. Ann. Glob. Health 81: 645-653. https://doi.org/10.1016/j.aogh.2015.08.014
  4. Gamblin SJ, Skehel JJ. 2010. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J. Biol. Chem. 285: 28403-28409. https://doi.org/10.1074/jbc.R110.129809
  5. Chap ple K J, Hendrick AE, McCarthy MW. 2000. Zanamivir in the treatment and prevention of influenza. Ann. Pharmacother. 34: 798-801. https://doi.org/10.1345/aph.19343
  6. Du QS, Huang RB, Wang SQ, Chou KC. 2010. Designing inhibitors of M2 proton channel against H1N1 swine influenza virus. PLoS One 5: e9388. https://doi.org/10.1371/journal.pone.0009388
  7. Alvarado-Facundo E, Gao Y, Ribas-Aparicio RM, Jimenez-Alberto A, Weiss CD, Wang W. 2015. Influenza virus M2 protein ion channel activity helps to maintain pandemic 2009 H1N1 virus hemagglutinin fusion competence during transport to the cell surface. J. Virol. 89: 1975-1985. https://doi.org/10.1128/jvi.03253-14
  8. He W, Han H, Wang W, Gao B. 2011. Anti-influenza virus effect of aqueous extracts from dandelion. Virol. J. 8: 538. https://doi.org/10.1186/1743-422X-8-538
  9. Jeon SW, Han C. 2015. Psychiatric symptoms in a patient with influenza A (H1N1) treated with oseltamivir (Tamiflu): a case report. Clin. Psychopharmacol. Neurosci. 13: 209-211. https://doi.org/10.9758/cpn.2015.13.2.209
  10. Morimoto K, Nagaoka K, Nagai A, Kashii H, Hosokawa M, Takahashi Y, et al. 2015. Analysis of a child who developed abnormal neuropsychiatric symptoms after administration of oseltamivir: a case report. BMC Neurol. 15: 130. https://doi.org/10.1186/s12883-015-0393-2
  11. Kim EJ, Yoon YP, Woo KW, Kim JH, Min SY, Lee HJ, et al. 2016. Verticine, ebeiedine and suchengbeisine isolated from the bulbs of Fritillaria thunbergii Miq. inhibited the gene expression and production of MUC5AC mucin from human airway epithelial cells. Phytomedicine 23: 95-104. https://doi.org/10.1016/j.phymed.2015.12.016
  12. Wang D, Zhu J, Wang S, Wang X, Ou Y, Wei D, et al. 2011. Antitussive, expectorant and anti-inflammatory alkaloids from Bulbus Fritillariae Cirrhosae. Fitoterapia 82: 1290-1294. https://doi.org/10.1016/j.fitote.2011.09.006
  13. Ozcelik B, Gurbuz I, Karaoglu T, Yesilada E. 2009. Antiviral and antimicrobial activities of three sesquiterpene lactones from Centaurea solstitialis L. ssp. solstitialis. Microbiol. Res. 164: 545-552. https://doi.org/10.1016/j.micres.2007.05.006
  14. Hurt AC, Baas C, Deng YM, Roberts S, Kelso A, Barr IG. 2009. Performance of influenza rapid point-of-care tests in the detection of swine lineage A(H1N1) influenza viruses. Influenza Other Respir. Viruses 3: 171-176. https://doi.org/10.1111/j.1750-2659.2009.00086.x

Cited by

  1. Identifying Active Compounds and Targets of Fritillariae thunbergii against Influenza-Associated Inflammation by Network Pharmacology Analysis and Molecular Docking vol.25, pp.17, 2020, https://doi.org/10.3390/molecules25173853